Pediatric Labeling Negotiations Limited To Six Months In Reauthorization Bill
This article was originally published in The Tan Sheet
Executive Summary
Negotiations for pediatric labeling changes would be limited to six months under a proposed bill to reauthorize the pediatric exclusivity provisions.
You may also be interested in...
FDA Pediatric Therapeutics Office Could Fall Under ORM Purview
FDA's Office of Pediatric Therapeutics would be located within the Office of Review Management under proposed organizational changes at the agency.
FDA Pediatric Therapeutics Office Could Fall Under ORM Purview
FDA's Office of Pediatric Therapeutics would be located within the Office of Review Management under proposed organizational changes at the agency.
FDA Pediatric Therapeutics Office Could Fall Under ORM Purview
FDA's Office of Pediatric Therapeutics would be located within the Office of Review Management under proposed organizational changes at the agency.